EMG
GNMK

Ellington Management Group’s GenMark Diagnostics, Inc GNMK Stock Holding History

Ellington Management Group’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,400
Closed -$66K – 754
2018
Q2 		$66K Buy
+10,400
New +$68.7K ﹤0.01% 465
2013
Q3 		– Sell
-61,700
Closed -$638K – 1034
2013
Q2 		$638K Buy
+61,700
New +$851K 0.12% 220

Other funds holding GNMK

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Ellington Management Group's GNMK Position: Q3 2018 in Review

Ellington Management Group sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2018, closing a stake of 10,400 shares — an estimated $66K sold.

Ellington Management Group first reported a position in GNMK in Q2 2013 and held it in 2 quarters. The position peaked at $638K in Q2 2013. 106 funds tracked by Wall St. Rank hold GNMK as of Q3 2018.

  • Ellington Management Group reported no remaining GenMark Diagnostics, Inc position as of Q3 2018 after selling out during the quarter.
  • Ellington Management Group sold 10,400 GenMark Diagnostics, Inc shares in Q3 2018, an estimated $66K.
  • Ellington Management Group first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 2 quarters.
  • Ellington Management Group's GenMark Diagnostics, Inc position peaked at $638K in Q2 2013.
  • 106 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2018.

Based on Ellington Management Group's 13F filing for Q3 2018, filed 14 Nov 2018.